HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE

Clinical trials for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE explained in plain language.

Never miss a new study

Get alerted when new HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE trials appear

Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Terminated trial tests new hope for Tough-to-Treat breast cancer

Disease control Terminated

This study aimed to see if a drug called repotrectinib, given with or without another drug called fulvestrant, could help control metastatic lobular breast cancer in people whose cancer had progressed after standard hormone-based treatments. It was a Phase 2 trial that enrolled o…

Matched conditions: HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 30, 2026 14:29 UTC

HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE

Get alerted when new HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE trials appear

Terminated trial tests new hope for Tough-to-Treat breast cancer